Wankhede Stadium Turns 50: Sugee Group and MCA Join in Celebrating a Historic Milestone
Mumbai, January 24, 2025: The Wankhede Stadium, a cornerstone of Indian cricket history, came alive with emotion, nostalgia, and celebration as the Mumbai Cricket Association (MCA) marked its 50th anniversary on January 19, 2025. The iconic venue hosted a grand spectacle, presented by Sugee Group as the Title Sponsor, celebrating five decades of cricketing excellence.
The mesmerizing evening, hosted by Mandira Bedi, Prasanna Sant, and Jatin Sapru, featured captivating performances by renowned artists Avadhoot Gupte and Ajay-Atul, along with a spectacular laser show, offering an unforgettable experience for the audience.
Established in 1974, the iconic stadium has witnessed numerous historic cricketing moments, etching its name firmly in modern cricket history. The event brought together cricket legends across generations, including Sunil Gavaskar, Sachin Tendulkar, Rohit Sharma, Ravi Shastri, Ajinkya Rahane, Diana Edulji, Shreyas Iyer, Yashasvi Jaiswal among others. Fans experienced heartfelt moments, a magnificent tribute to Wankhede’s illustrious legacy, and an inspiring vision of hope for the future of Indian cricket.
Cricketing legends and captains, past and present, echoed their sentiments, while groundsmen and support staff were honoured. All echoed the significance the stadium has had in shaping their career and India’s overall cricketing journey. The essence of Mumbai’s cricketing legacy which produces talented players year-on-year, also came to the forefront in deliberations among the star players.
Sugee Group Founder and Managing Partner, Mr. Nishant Deshmukh, expressed immense pride in partnering with MCA for this milestone celebration, stating, “Wankhede Stadium is not just a landmark; it is the soul of Mumbai’s cricketing passion and a living embodiment of the city’s rich cultural heritage. To be part of such a historic occasion is a moment of immense honour and deep gratitude for Sugee Group. This celebration resonates with our core values of enriching lives, preserving legacies, and fostering connections that transcend time. Contributing to this iconic event was a heartfelt tribute to Mumbai’s spirit and the timeless memories it creates for generations.”
MCA President Shri Ajinkya Naik added, “The support of Sugee Group as our Title Sponsor elevated the grandeur of this celebration. Their dedication to Mumbai’s development complements the spirit of Wankhede Stadium, and together, we delivered an unforgettable experience to cricket enthusiasts across the nation.”
Embryolisse Launches Filaderme: A New Era of Skin Hydration
January 2025: Embryolisse, a specialist in multi-tasking skin care, is proud to announce the launch of Filaderme, a transformative cream designed to rejuvenate dry and sensitive skin. This revolutionary product is set to redefine skincare routine with its powerful lipid-replenishing formula that restores the skin’s protective lipidic film and fortifies the skin barrier.
Say goodbye to dryness and flakiness. Filaderme is enriched with 90% natural origin ingredients to shield your skin from harsh weather changes while maintaining its strength and moisturization power. Its luxuriously smooth texture and pleasant almond fragrance deliver a delightful sensory experience alongside unmatched hydration and repair. Filaderme is a testament to Embryolisse’s commitment to creating effective and gentle skincare solutions for all skin types. Infused with a lipid-replenishing formula and the benefits of 99% ingredients from natural origin, such as Shea butter, Aloe vera, Soy proteins, and others- Filaderme Emulsion cream is a must-have, it helps to impart long-lasting nourishment to dry and extremely dry skin.
Filaderme – a Game-Changer
Immediate and Lasting Nourishment: The lipid-replenishing formula works instantly to soothe and hydrate dry skin, ensuring long-lasting comfort.
Repairs Dry and Very Dry Skin: The rich blend of essential nutrients restores the skin’s natural balance, making it an ideal solution for even the most sensitive skin.
Comfort Redefined: Feelings of discomfort and tightness disappear, replaced by a sensation of smoothness and ease.
Clinical Benefits
- Nourishes and replenishes the skin deeply
- Strengthens the skin barrier, ensuring lasting hydration
- Eliminates signs of dryness and flakiness
- Protects against external aggressors
- Leaves skin feeling soft, supple, and radiant
Experience the best of French pharmacy skincare with Embryolisse. Renowned for its science-backed formulations and dedication to simplicity, Embryolisse offers a unique blend of dermatological expertise and natural ingredients. Trusted by pharmacists, dermatologists, and make-up artists around the world, the brand has been a cornerstone of French beauty for decades. Embryolisse Filaderme Emulsion is available in-store and online via Nykaa, Blinkit, Flipkart, Zepto, and Amazon.
New Bengaluru Office to Accelerate St. Fox’s Cybersecurity Innovation and Growth
Bangalore, 24th January 2025 – St. Fox, a rapidly growing cybersecurity consultancy built on the principles of fearless innovation and relentless protection, is thrilled to open its new office in Bangalore. Headquartered in Pune, the company sets footprint in Bangalore marking its 2nd office in India. The 100-seater office premises at HSR Layout, Bangalore, will be primarily supporting its R&D and client delivery teams. The new office is designed with sustainability and employee’s well-being in mind, leveraging renewable energy sources and energy-efficient infrastructure. Adopting Green Building Practices, the workspace includes ergonomic setups, wellness zones, and collaboration hubs to foster productivity and innovation among the employees.
Ronak Maniar, Founder and Managing Director of St. Fox, said, “We are excited to open our new office in Bangalore, the hub for IT sector and one of the key businesses & talent market for us. As part of our long-term growth strategy, expanding into Bangalore will enable us to further accelerate our already rapidly growing business. We believe the most important challenge facing us today is the need to secure our rapidly expanding digital ecosystem while fostering innovation. With cyberattacks becoming more sophisticated and frequent, we aim to expand our offerings, particularly in areas like AI-driven security, blockchain integration, and advanced data protection. We are committed to ensuring that our solutions evolve alongside the rapidly changing technological landscape, enabling our clients to not only protect their digital assets but also leverage new technologies to drive growth.
With a current workforce of over 120 SMEs across India, St. Fox continues to strengthen its capabilities in cybersecurity consulting, AI innovation, and technical consulting. Aiming to expand its India team to over 300 employees by 2026, the company has partnered with premier institutions across to nurture cybersecurity and AI talent. To address the cybersecurity talent gap, St. Fox has invested in continuous learning and development programs to ensure the team remains at the forefront of industry trends and advancements. The training and mentorship program aims to cultivate the next generation of cybersecurity leaders.
St. Fox’s headquarters at Pune, spans over 7,000 sq. ft. at one of the premium IT parks and can accommodate over 200 employees. As part of its ambitious growth strategy, the organization plans to open offices in Hyderabad and Mumbai by 2026 to tap into regional talent and business. Additionally, client engagement centers are set to be launched later this year in Dubai and Singapore, enhancing international collaboration and expanding global operations.
5 fintech Stocks to Watch in 2025: Big Gains Ahead
As we move into 2025, the financial markets are teeming with opportunities, especially in the rapidly expanding fintech and digital lending sectors. Technology-driven solutions, coupled with shifting consumer behavior and a strong push for digital financial services, are creating a hotbed for growth. For investors looking to make big gains, some stocks in the fintech space are showing exceptional promise. In this article, we’ll take a look at five stocks to watch in 2025, each poised to benefit from the accelerating digital transformation in finance.
1. lendingplate (Unifinz Capital India Limited) – A Digital Lending Powerhouse| Stock price: ₹563
lendingplate, under Unifinz Capital India Limited, is one of the most promising companies in India’s digital lending space. Offering unsecured personal loans up to ₹2,50,000 with flexible repayment options up to 15 months, the platform has been gaining traction with consumers looking for fast, hassle-free credit solutions. lendingplate has already disbursed ₹500 crore in loans year-to-date, showcasing its significant impact on the digital lending landscape. As of now, the stock price of Unifinz Capital India Limited (UCIL), lendingplate stands at ₹563, making it an attractive investment opportunity in the digital lending sector.
lendingplate primarily caters to individuals who are overlooked by traditional banks, and a significant portion of its loan portfolio comprises borrowers with thin credit or low credit scores. This unique focus positions lending plates to tap into the vast underserved market in India, providing access to credit for those who typically struggle to get loans through conventional channels.
One of Lendingplate’s standout features is its ability to offer instant loan approvals and disbursements within 30 minutes, which is incredibly appealing to customers who need quick access to funds. The company’s customer-centric approach, combined with its digital-first model, allows it to offer flexible loan amounts and repayment terms tailored to individual needs.
lendingplate is servicing 5000+ pin codes across 17 states, giving it a broad reach in urban and rural markets alike. With its ability to tap into the growing demand for unsecured credit, the company is well-positioned to continue expanding its customer base and loan disbursements as it targets further growth in 2025.
2. Aavas Financiers – Revolutionizing Affordable Housing Loans| Stock price: ₹1,686.10
Aavas Financiers has carved out a strong niche in providing affordable housing loans to lower- and middle-income groups, focusing on Tier II and Tier III cities. The company’s emphasis on digital underwriting and innovative loan disbursement methods is helping to drive growth. As government policies continue to support affordable housing, Aavas Financiers is well-positioned to capitalize on the growing demand for housing loans in India.
With a solid growth trajectory and a focus on financial inclusion, Aavas Financiers is a strong contender for significant gains in 2025.
3. Bajaj Finance – A Leader in Consumer Finance with Digital Innovation| Stock price: ₹7,182.10
Bajaj Finance has long been one of India’s top non-banking financial companies (NBFCs), offering everything from personal loans to business loans and consumer durables financing. The company’s relentless push towards digitalization has kept it at the forefront of India’s consumer finance sector. With its strong customer base, tech-driven credit solutions, and a growing loan book, Bajaj Finance is a stock worth keeping an eye on in 2025, especially as the demand for instant and unsecured credit rises.
Bajaj Finance’s innovative lending models and strong market presence position it for impressive growth in the coming years.
4. HDFC Bank – Traditional Banking Meets Fintech Innovation| Stock price: ₹4,030.85
HDFC Bank is one of India’s most respected private-sector banks, and its entry into the digital lending space has been nothing short of transformative. By integrating artificial intelligence (AI) and machine learning (ML) into its loan origination processes, HDFC Bank has significantly streamlined its loan approval process, making it faster and more efficient. The bank’s strong digital infrastructure enables it to reach a larger audience, particularly in rural areas, while still maintaining its stronghold in urban markets.
HDFC Bank’s ability to blend traditional banking expertise with cutting-edge fintech solutions makes it an attractive stock for investors in 2025.
5. Paytm (One97 Communications ltd.) – The Fintech Giant Expanding Its Lending Footprint| Stock price: ₹900.15
Paytm continues to dominate India’s digital payment space and is rapidly expanding into lending, insurance, and wealth management. With its vast user base, Paytm has the unique opportunity to cross-sell lending products such as personal loans, merchant loans, and buy-now-pay-later (BNPL) services. By leveraging its existing platform, Paytm is positioned to take full advantage of India’s booming digital lending ecosystem, especially as credit penetration continues to grow.
As India’s largest mobile payment platform, Paytm is looking to expand its digital lending capabilities in 2025, making it a key player in the rapidly evolving fintech space.
Disclaimer: This is for informational purposes only and should not be construed as investment advice. Please conduct your own research or consult a financial advisor before making any investment decisions
Agilus Diagnostics Redefines Myeloid Malignancy Testing with India’s 3-Day Genomic Results
24 January 2025: Agilus Diagnostics, India’s largest and most trusted diagnostic network, announces a ground-breaking achievement in genomic testing with its industry-leading 3-day turnaround time (TAT) for test results in myeloid malignancies.
The genomic testing market in India is experiencing rapid growth, driven by advancements in technology, increasing awareness, and the rising demand for personalized medicine. Currently valued at approximately USD 150 million, the market is projected to grow at a CAGR of over 15% in the next five years. Genomic testing is transforming cancer diagnostics by revolutionizing targeted therapy and personalized medicine. By providing actionable insights into an individual’s unique genetic profile, it enables clinicians to identify specific mutations, tailor treatment plans, and select therapies that offer the highest efficacy. As the future of cancer diagnostics, genomic testing empowers early detection, precise interventions, and better disease management, marking a significant shift in how cancer care is delivered. With these advancements, Agilus Diagnostics’ cutting-edge offerings place it at the forefront of this expanding market. By delivering unparalleled speed and precision, the company is well-positioned to capitalize on the growing demand for genomic testing in India, establishing itself as a leader in the space.
Next Generation Sequencing (NGS) is revolutionizing genetic testing by enabling precise, comprehensive analysis of genetic variations, empowering clinicians with actionable insights for personalized patient care. While genomic testing has traditionally been a lengthy process, often taking weeks to deliver results, Agilus Diagnostics has set a new benchmark by delivering individualized reports—meticulously crafted by expert molecular pathologists—in just three days (for myeloid malignancies). This rapid turnaround ensures faster clinical decision-making, ultimately improving patient outcomes and setting us apart as leaders in precision diagnostics.
The Myeloid Genomics Testing and Precision Assay is designed to offer faster, more precise insights into cancer and myeloid disorders. The Myeloid Genomics Testing covers 79 genes, including those linked to inherited risks, to detect key genetic changes like mutations and fusions. This enables personalized treatment recommendations for conditions like Acute Myeloid Leukemia (AML) and Myeloproliferative Neoplasms (MPN). Reports are reviewed by expert pathologists and include internationally recognized risk assessment tools and therapy suggestions tailored to the patient.
The Genomic Profiling Precision Assay provides comprehensive genomic profiling for cancers like lung, colon, breast, and melanoma by analyzing 50 critical genes. It identifies mutations, amplifications, and fusion genes, offering actionable insights for targeted treatments. With optimized panels for tissue and blood samples, the test ensures accurate results within 2 days for liquid biopsy samples and 7 days for tissue block samples, making it a powerful tool for precision medicine.
“Our 3-day genomic testing initiative for myeloid malignancies addresses one of the biggest challenges in precision oncology —Time. With this breakthrough, Agilus Diagnostics is not only setting a new industry standard but also transforming patient care by enabling faster diagnoses and treatment,” said Dr. Anand K, Managing Director & CEO of Agilus Diagnostics.
Currently, the labs in the genomic testing space often take up to 2 -3 weeks to deliver results for myeloid malignancies, which can delay critical clinical decisions. In contrast, Agilus Diagnostics’ rapid testing approach significantly shortens the diagnostic timeline, reducing hospital visits and enhancing the patient experience.
Driving Global Standards in Genomic Testing
Agilus Diagnostics’ commitment to speed and precision extends beyond technological advancements. The company ensures that every report is individualized, with expert molecular pathologists meticulously interpreting results. This personalized reporting approach ensures that physicians receive not just data but clinically actionable insights that support timely and effective patient management.
Agilus Diagnostics is setting new benchmarks in genomic testing, aligning with global standards in personalized medicine. The combination of advanced technology, rapid turnaround times, and expert oversight positions the company as a leader in precision diagnostics. By offering unparalleled speed, accuracy, and patient-focused care, Agilus Diagnostics reaffirms its commitment to bringing world-class diagnostic services to India.
“With our advanced genomic testing capabilities, we aim to provide clinicians with the tools they need to make timely, informed decisions. This not only improves outcomes but also sets a new benchmark for the healthcare industry in India,” added Dr. Anand K.
Timely Surgery Transforms 11-Year-Old’s Life After Moyamoya
Bangalore, 24th January, 2025: In a compelling case that underscores the importance of early diagnosis and expert intervention, an 11-year-old boy from Devanahalli Taluk, overcame the challenges posed by Moyamoya disease—a rare cerebrovascular disorder often leading to continuous strokes. Known to have a prevalence rate of 0.35 to 0.94 per 100,000 people, mainly in the areas of Japan and Korea, Moyamoya disease manifests itself via gradual narrowing of arteries supplying blood to the brain. Arjun (name changed) experienced an episode of seizure a year back which was progressively followed by a decline in his ability to see and weakness on the left side of his body over the course of the year. A CT Angiogram at Aster Whitefield Hospital showed a “puff of smoke” appearance – a hallmark sign of Moyamoya disease, hence confirming the diagnosis.
This rare and unique disease mostly affects children around the age of 10 years and adults around the age of 40 years while progressing without warning, necessitating prompt and precise medical intervention. Moyamoya disease causes narrowing of key brain arteries, prompting the brain to form smaller compensatory blood vessels to meet its oxygen needs. These new vessels, however, are often insufficient, appearing as a “puff of smoke” in imaging scans. When the brain’s demand for blood outpaces the supply, patients experience strokes or other neurological events, as in Arjun’s case. Left untreated, Moyamoya can lead to recurring strokes, disability, and even death, making early diagnosis critical to altering the disease’s course.
Recognizing the immediacy of the situation, the medical team decided to go ahead with a Revascularization surgery. This is an intricate procedure but offers a reliable method to restore blood flow to the brain. The surgeons carefully isolated a scalp artery, called the superficial temporal artery (STA) and connected it to an artery in the brain, creating an anastomosis. This connection enabled blood from the STA to eventually supply the brain, circumventing the narrowed arteries and improving oxygen delivery. But, the surgery was not without its challenges. Revascularization demanded careful handling of delicate arteries. Isolating them and suturing these tiny vessels required flawless execution. Through the combined expertise of Dr. Swaroop Gopal, Group Director – Aster International Institute of Neurosciences and Spine Care, Aster Whitefield Hospital, Specializing in Vascular and Endo-Vascular Surgery and Dr. Suraj Gopal, Associate Consultant, Neurosurgery, Aster Whitefield Hospital the surgery was completed successfully.
The post-operative prognosis for this disease includes stabilization of the symptoms with continuous evaluation. Arjun was discharged two days after his surgery and has been scheduled for regular check-ups to monitor his condition as Moyamoya disease is known to be bilateral, that is, it affects both the sides of the brain. Hence, there is a possibility that revascularization procedures may be needed for the opposite side of the brain as well.
“Arjun is doing well now. After the diagnosis, a Digital Subtraction Angiography (DSA) was performed to evaluate issues with the blood flow. This involved inserting a catheter into the leg artery and guiding it to the brain’s blood vessels, utilizing high-quality X rays to image the blood vessels”, mentioned Dr. Swaroop Gopal, Group Director – Aster International Institute of Neurosciences and Spine Care, Aster Whitefield Hospital. “The whole revascularization procedure was done under a microscope”, he added.
Arjun’s family were kept informed of all the developments and treatment plans on a daily basis. The rarity of the case made it a challenge for them to understand the condition and the need for surgery. But considerable information, reassurance and support from the medical team provided the parents with emotional strength to face the situation. Throughout the whole process they remained hopeful and strong.
Dr. Suraj Gopal, Associate Consultant, Neurosurgery, Aster Whitefield Hospital, mentioned, “Moyamoya is a surgically treatable disease. Hence, it is very important for parents, guardians or family to not dismiss the symptoms as a typical paralysis or stroke. Early recognition of the symptoms is crucial for the diagnosis and subsequent treatment. Missing symptoms increases the risk of recurrence, with strokes becoming more severe and occurring in closer intervals.”
Arjun has completely recovered from the weakness that had affected the left side of his body along with partial improvement in his vision, as the bypass starts functioning several weeks after the surgery. With timely intervention, advanced surgical techniques, and compassionate support, Arjun’s future is now full of possibilities. The success of his treatment offers hope to other families facing similar diagnoses, showcasing how expert care and determination can change lives.
Kamya Panjabi on National Girl Child Day: A Call for Real Progress in Gender Equality
In a world where days like National Girl Child Day and Women’s Day are marked with enthusiasm, Kamya Panjabi, known for her role as Mohini in Ishq Jabariya on Sun Neo, brings a thought-provoking perspective. While many celebrate these days with grandeur and big speeches, Kamya questions their true impact. Her honest words remind us that change begins with actions, not just words.
Kamya says, “I feel that celebrating things like National Girl Child Day and Women’s Day is just a joke. Honestly, it feels like a waste of time. All this big talk about girl’s rights and equality it needs to stop unless we actually do something about it. The day our mindset truly changes, the day these things start happening for real, we won’t need a specific day to celebrate girls or women. Every single day will naturally become a celebration. We keep saying that the country is progressing, that things are improving, and yes, they are. But the reality is that the mindset hasn’t changed much. It’s still stuck in the past.”
She reflects on her own fears as a mother, saying, “Take my own fears as an example. Even today, if my daughter has to step out of the house, I feel scared. I worry about sending her with a driver. She’s only 15 now, but when she turns 18, my fears will only grow. That worry has already started. Why? Because we don’t have trust. There’s no faith in our society. Someone could die, get assaulted, or even worse, and it seems like life just moves on. Cases like Nirbhaya keep happening, and it makes me so angry.”
The Ishq Jabariya actress powerfully states, “When we talk about girls and their safety, it makes my blood boil. We celebrate and talk about progress, but the truth is, the basic fear and mistrust haven’t gone away. Until those things change, what’s the point of celebrating?”
In Ishq Jabariya, Kamya plays Mohini, the aunt of Aditya (Lakshay Khurana). The show follows the heartwarming journey of Gulki (Siddhi Sharma), a lively young woman with big dreams who faces unexpected challenges on her path to love and self-discovery.
Managing Winter Risks and Staying Strong for Cancer Patients
By:Dr Raghav Kesri, Senior Consultant and Head Medical Oncology, Yatharth Hospital, Greater Noida
Cancer treatment can be a challenging journey for patients, and the winter months often add an extra layer of difficulty. The drop in temperatures and the onset of seasonal illnesses pose unique risks for individuals undergoing cancer treatment or recovering from it. Understanding how cold weather affects cancer patients and taking appropriate precautions is essential for managing health during this season.
Cold Weather and Its Effect on Cancer Patients
The colder months can significantly affect the overall well-being of cancer patients. One of the primary concerns is weakened immunity. Many cancer treatments, such as chemotherapy and radiation, suppress the immune system, making patients more susceptible to seasonal infections like the flu and pneumonia. Exposure to extreme cold can also lead to complications like frostbite and hypothermia, especially for those with reduced circulation due to treatment side effects.
Cancer survivors often experience joint pain and stiffness as a result of treatment-induced inflammation or side effects like peripheral neuropathy. Cold temperatures tend to exacerbate these conditions, leading to discomfort and reduced mobility. Additionally, reduced exposure to sunlight during winter may cause a drop in vitamin D levels, which are essential for immune function and bone health.
Managing Risks During the Winter
To navigate the challenges posed by winter, cancer patients can adopt several strategies to protect their health. Keeping the body warm is crucial. Wearing multiple layers of clothing, using heating devices indoors, and avoiding prolonged exposure to cold weather can help prevent complications like frostbite and hypothermia.
Maintaining a strong immune system is vital during this time. A well-balanced, nutrient-rich diet that includes plenty of fruits, vegetables, and antioxidant-rich foods can help boost immunity. Incorporating foods fortified with vitamin D or taking supplements, as prescribed by a doctor, can address seasonal deficiencies.
Preventing infections is another critical step. Cancer patients should prioritize hygiene by washing their hands regularly, avoiding crowded spaces, and staying up-to-date with seasonal vaccinations, such as flu shots. Staying hydrated and using humidifiers can also help combat dry air, which can irritate respiratory passages and skin.
Mental Health and Emotional Well-Being
The colder months, combined with the physical toll of cancer treatment, can also affect mental health. Seasonal affective disorder, characterized by feelings of depression during winter, can exacerbate the emotional challenges that many cancer patients face. Engaging in regular physical activity, such as indoor yoga or light exercises, can help improve mood and circulation. Practices like mindfulness, meditation, and counselling can also provide emotional support during this difficult time.
Road to Recovery
For cancer patients, managing the effects of cold weather requires a proactive approach. Taking steps to stay warm, maintain immunity, and prioritize mental health can make a significant difference in their overall well-being. It is equally important to stay in close communication with healthcare providers, who can offer tailored advice and interventions to address individual risks during the winter months.
While winter poses unique challenges, it is also an opportunity to focus on self-care and resilience. With the right precautions, cancer patients can navigate the season safely and continue their journey toward recovery.
Telangana Signs MoU with JSW Defence for Manufacturing Facility
Chandigarh, January 24, 2025: The Government of Telangana has entered into a Memorandum of Understanding (MoU) with JSW UAV Limited, a wholly-owned subsidiary of JSW Defence, to establish a state-of-the-art manufacturing facility to make Unmanned Aerial Systems (UAS) in the state.
As part of this strategic initiative, JSW UAV is set to invest approximately ₹800 crores in the project, through a technology arrangement with a leading US-based defence technology company.
The MoU was signed in the presence of the Honorable Chief Minister of Telegana, Shri Revant Reddy and Parth Jindal of JSW Group in the presence of senior dignitaries from the state on the side lines of the ongoing World Economic Forum (WEF) at Davos.
Speaking on the occasion, Shri Revanth Reddy, Honorable Chief Minister of Telengana, said, “Hyderabad, and Telengana, was long positioned in the global market as software and pharma leader. With clear vision and diligent efforts, we are now establishing Telengana as a clear leader for investments in manufacturing across sectors, ranging from semiconductor, defence, private space to FMCG. My government’s efforts to position Telengana as a preferred option for the world for its China Plus One strategy has started bearing results.”
Parth Jindal of JSW Group said, “This MoU underscores our unwavering commitment to playing a key role in indigenizing defense technology in India. We are deeply grateful to the Government of Telangana, led by the Honorable Chief Minister Shri Revanth Reddy, for its guidance and support through industry-friendly policies that make initiatives like this possible.”
JSW Defence Pvt Ltd. – a part of the US$ 24 billion JSW Group – has a strategic partnership with Shield AI, Inc, a leading U.S defence technology company, to indigenize and manufacture Shield AI’s “V-BAT”, a Group 3 Unmanned Aerial System (UAS). This collaboration marks a significant step in boosting India’s defence capabilities by bringing in world-class UAS technology to the country.